ATLANTA — The CDC’s Advisory Committee on Immunization Practices (ACIP) voted in favor of including the new 9-valent HPV strain vaccine in its recommendations about HPV immunization.
And in other votes at the weather-shortened meeting here, the panel voted to recommend meningococcal group B vaccines only for high-risk groups, including individuals in “outbreak areas,” and dialed back its recommendation of the live attenuated influenza vaccine (LAIV) to “no preference” compared to the inactive vaccine.
The 9-valent HPV strain vaccine (Gardasil-9) was licensed in December for use in females ages 9 to 26 and males ages 9 to 15. The new vaccine targets five additional strains of HPV, which adds protection against 14% of additional HPV cancers in women and 5% additional HPV cancers in men. The committee reviewed clinical trials showing the efficacy of the 9-valent HPV vaccine was about 97% compared with the current 4-valent HPV vaccine, and it was more cost-effective as well.
READ FULL ARTICLE From Medical Page Today